Table 1. Demographic and Baseline Clinical Characteristics.
| Galantamine | Oxytocin | Placebo | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Measure | N | Mean | S.D. | N | Mean | S.D. | N | Mean | S.D. |
| Age, Yrs. | 20 | 45.8 | 12.4 | 16 | 47.4 | 11.2 | 20 | 42.2 | 11.7 |
| Age at 1st Psychotic Symptoms | 15 | 20.0 | 7.6 | 14 | 21.7 | 9.0 | 13 | 19.2 | 3.7 |
| Participant Education, years | 20 | 11.9 | 1.8 | 16 | 12.6 | 1.7 | 20 | 12.1 | 2.3 |
| Max. Parental Education, years | 17 | 12.2 | 2.7 | 16 | 13.2 | 3.5 | 20 | 14.3 | 3.2 |
| Measure | n | N | % | n | N | % | n | N | % |
| Sex, (% female) | 6 | 20 | 30 | 2 | 16 | 12.5 | 3 | 20 | 15.0 |
| Race | |||||||||
| African-American | 10 | 20 | 50.0 | 8 | 16 | 50.0 | 7 | 20 | 35.0 |
| White | 10 | 20 | 50.0 | 7 | 16 | 43.8 | 13 | 20 | 65.0 |
| Native American | 0 | 20 | 0.0 | 1 | 16 | 6.2 | 0 | 20 | 0.0 |
| Diagnosis (% schizophrenia) | 17 | 20 | 85.0 | 15 | 16 | 93.8 | 18 | 20 | 90.0 |
| Baseline Antipsychotics | |||||||||
| Aripiprazole | 1 | 19* | 5.3 | 1 | 16 | 6.2 | 3 | 20 | 15.0 |
| Clozapine | 5 | 19 | 26.3 | 4 | 16 | 25.0 | 6 | 10 | 30.0 |
| Haloperidol | 0 | 19 | 0.0 | 1 | 16 | 6.2 | 2 | 20 | 10.0 |
| Olanzapine | 4 | 19 | 21.0 | 3 | 16 | 18.8 | 3 | 20 | 15.0 |
| Quetiapine | 1 | 19 | 5.3 | 2 | 16 | 12.5 | 1 | 20 | 5.0 |
| Risperidone | 5 | 19 | 26.3 | 5 | 16 | 31.2 | 5 | 20 | 25.0 |
| Polypharmacy** | 3 | 19 | 15.8 | 3 | 16 | 18.8 | 3 | 20 | 15.0 |
| Mood Stabilizers | 1 | 19 | 5.3 | 2 | 16 | 12.5 | 2 | 20 | 10.0 |
| Antidepressants | 3 | 19 | 15.8 | 2 | 16 | 12.5 | 8 | 20 | 40.0 |
*
Baseline psychotropic medication use was missing for one participant assigned to galantamine
**
Participants on polypharmacy are included in the total number of users reported for each medication. One participant assigned to galantamine used both risperidone and olanzapine, and two used both risperidone and clozapine; one participant assigned to oxytocin used both haloperidol and olanzapine, one used both risperidone and quetiapine, and one used both risperidone and clozapine; one participant assigned to placebo used both haloperidol and clozapine, and two used both risperidone and clozapine.